#1 Clinical Trials Search in Europe

Donepezil Hydrochloride

This article examines the use of Donepezil Hydrochloride, also known as Aricept, in clinical trials for various neurological conditions. Donepezil is primarily studied for its effects on cognitive function, particularly in Alzheimer’s disease, dementia with Lewy bodies, and vascular dementia. The trials explore its efficacy, safety, and potential benefits in improving memory, attention, and daily functioning in patients with these conditions.

Table of Contents

What is Donepezil Hydrochloride?

Donepezil Hydrochloride, also known by its brand name Aricept or its research code E2020, is a medication primarily used to treat cognitive symptoms associated with various forms of dementia[1]. It belongs to a class of drugs called acetylcholinesterase inhibitors, which work by increasing the levels of a certain chemical in the brain that is important for memory and thinking[2].

Conditions Treated by Donepezil

Donepezil is primarily used to treat the following conditions:

  • Alzheimer’s Disease: It is most commonly prescribed for mild to severe Alzheimer’s disease, a progressive brain disorder that affects memory, thinking, and behavior[1][3].
  • Dementia with Lewy Bodies (DLB): This is another type of dementia characterized by abnormal protein deposits in the brain[4].
  • Cognitive Deficits in Autism: Some research is exploring its potential use in treating cognitive problems associated with autism spectrum disorders[5].

How Donepezil Works

Donepezil works by inhibiting an enzyme called acetylcholinesterase. This enzyme normally breaks down acetylcholine, a neurotransmitter (chemical messenger) in the brain that is important for memory, thinking, and reasoning. By blocking this enzyme, donepezil helps to maintain higher levels of acetylcholine in the brain, which may improve or stabilize symptoms of dementia for some time[2].

Dosage and Administration

Donepezil is typically available in tablet form and is usually taken once daily. The dosage may vary depending on the condition being treated and the individual patient’s response. Some common dosages include:

  • 5 mg daily, which may be increased to 10 mg daily after 4-6 weeks[2].
  • In some cases, doses may be increased up to 23 mg daily for moderate to severe Alzheimer’s disease[3].

It’s important to note that donepezil is also available as an orally disintegrating tablet, which can be taken with or without water[6]. Always follow your doctor’s instructions regarding dosage and administration.

Efficacy of Donepezil

The effectiveness of donepezil is typically measured using various cognitive and functional assessments. Some of the key measures used in clinical trials include:

  • Mini-Mental State Examination (MMSE): This test evaluates overall cognitive function, including orientation, memory, and attention. A higher score indicates better cognitive function[4].
  • Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog): This scale assesses a range of cognitive abilities. A lower score indicates better function[7].
  • Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus): This measures overall clinical function based on both clinician and caregiver observations[1].

Studies have shown that donepezil can help improve or stabilize cognitive function and daily living activities in some patients with Alzheimer’s disease and other forms of dementia. However, it’s important to understand that while donepezil can help manage symptoms, it does not cure or stop the progression of these diseases[1][3].

Potential Side Effects

Like all medications, donepezil can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Loss of appetite
  • Diarrhea
  • Muscle cramps
  • Fatigue
  • Difficulty sleeping

More serious side effects, though less common, can include slow heartbeat, fainting, and severe stomach problems. It’s important to report any side effects to your healthcare provider[3].

Use in Special Populations

Donepezil may be used with caution in certain populations:

  • Patients with kidney disease: Studies have been conducted to understand how donepezil is processed in patients with end-stage renal disease who are on hemodialysis[8].
  • Children and adolescents: While primarily used in adults, some research is exploring its potential use in children with autism spectrum disorders[5].

Ongoing Research

Researchers continue to study donepezil to understand its full potential. Some areas of ongoing research include:

  • Its use in combination with other medications for Alzheimer’s disease[7].
  • Its potential effectiveness in treating cognitive deficits in autism[5].
  • Its use in treating oxaliplatin-induced peripheral neuropathy in cancer survivors[9].

As with any medication, it’s crucial to discuss the potential benefits and risks of donepezil with your healthcare provider. They can provide personalized advice based on your specific health situation and needs.

Aspect Details
Main Conditions Studied Alzheimer’s Disease, Dementia with Lewy Bodies, Vascular Dementia, Autism Spectrum Disorder
Dosage Forms Oral tablets (3 mg, 5 mg, 10 mg)
Primary Outcome Measures Cognitive function (MMSE, ADAS-cog), Global clinical function (CIBIC-plus)
Secondary Outcome Measures Activities of Daily Living, Neuropsychiatric symptoms, Quality of life
Special Populations Patients with end-stage renal disease, Assisted living facility residents
Study Designs Randomized controlled trials, Open-label studies, Pharmacokinetic studies
Duration of Trials Ranging from 12 weeks to 24 weeks

FAQ

  • What is Donepezil Hydrochloride? Donepezil Hydrochloride, also known by the brand name Aricept, is a medication primarily used to treat symptoms of Alzheimer's disease and other forms of dementia. It works by increasing levels of a brain chemical called acetylcholine, which is important for memory and thinking.
  • What conditions are being studied with Donepezil in these clinical trials? The clinical trials are studying Donepezil's effects on various conditions, including Alzheimer's disease, dementia with Lewy bodies, vascular dementia, and autism spectrum disorder. Some studies also look at its use in patients with end-stage renal disease.
  • How is Donepezil administered in these trials? In most trials, Donepezil is administered orally as tablets. The dosage varies, but common doses include 3 mg, 5 mg, and 10 mg per day. Some studies start with a lower dose and increase it over time.
  • What are the main outcomes measured in these Donepezil trials? The trials primarily measure changes in cognitive function using scales like the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog), and various neuropsychiatric inventories. Some studies also assess daily living activities and quality of life.
  • Are there any side effects of Donepezil mentioned in these trials? While specific side effects are not detailed in the provided information, the trials include safety assessments. Common side effects of Donepezil can include nausea, diarrhea, and sleep disturbances. The studies monitor for adverse events and adjust dosages if needed.

Ongoing Clinical Trials on Donepezil Hydrochloride

  • Study on the Effects of Donepezil on Cognitive and Motor Functions in Elderly Patients with Neurological Disorders

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Donepezil for Mild Cognitive Impairment in Parkinson’s Disease Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Donepezil in Patients with Anorexia Nervosa

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Topical Donepezil Hydrochloride Cream for Safety and Effectiveness in Adult Patients with Acne Vulgaris

    Not recruiting

    2 1
    Investigated drugs:
    Denmark

  • Study on the Effects of Phenserine and Donepezil in Patients with Early or Mild Alzheimer’s Disease

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Norway

Glossary

  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This helps determine the proper dosage and frequency of medication administration.
  • Alzheimer's Disease: A progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia in older adults.
  • Dementia with Lewy Bodies (DLB): A type of progressive dementia that leads to a decline in thinking, reasoning, and independent function. It is characterized by the presence of abnormal clumps of protein called Lewy bodies in the brain.
  • Vascular Dementia: A decline in thinking skills caused by conditions that block or reduce blood flow to various regions of the brain, depriving them of oxygen and nutrients.
  • Mini-Mental State Examination (MMSE): A widely used test of cognitive function among older adults. It includes questions to assess orientation, memory, attention, and language.
  • Neuropsychiatric Inventory (NPI): An assessment tool used to evaluate behavioral and psychological symptoms in patients with dementia or other neurological disorders.
  • Clinician's Interview-Based Impression of Change (CIBIC): A global assessment tool used to measure change in a patient's overall clinical status, often used in dementia studies.
  • Activities of Daily Living (ADL): Routine activities that people tend to do every day without needing assistance, such as eating, bathing, dressing, and toileting. These are often assessed in dementia studies to measure functional ability.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the active drug being tested.
  • Bioequivalence: The absence of a significant difference in the rate and extent to which the active ingredient in pharmaceutical equivalents becomes available at the site of drug action when administered at the same dose under similar conditions.

References

  1. https://clinicaltrials.gov/study/NCT00165659
  2. https://clinicaltrials.gov/study/NCT00165750
  3. https://clinicaltrials.gov/study/NCT02097056
  4. https://clinicaltrials.gov/study/NCT00543855
  5. https://clinicaltrials.gov/study/NCT00047697
  6. https://clinicaltrials.gov/study/NCT01506752
  7. https://clinicaltrials.gov/study/NCT00710684
  8. https://clinicaltrials.gov/study/NCT01063556
  9. https://clinicaltrials.gov/study/NCT05254639